{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:15:57Z","timestamp":1784308557792,"version":"3.55.0"},"reference-count":62,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0665-2","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T10:02:42Z","timestamp":1566468162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6004-2614","authenticated-orcid":false,"given":"Aung","family":"Naing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikbel","family":"Achour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah","family":"Barbee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Morehouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Pollizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nairouz","family":"Elgeioushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Walcott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyson","family":"Karakunnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Weise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oberst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"key":"665_CR1","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365\u20139.","journal-title":"Nat Med"},{"key":"665_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261\u20138.","journal-title":"Nat Immunol"},{"key":"665_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"665_CR4","doi-asserted-by":"crossref","first-page":"56233","DOI":"10.18632\/oncotarget.9316","volume":"7","author":"H Zheng","year":"2016","unstructured":"Zheng H, Liu X, Zhang J, Rice SJ, Wagman M, Kong Y, et al. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget. 2016;7:56233\u201340.","journal-title":"Oncotarget."},{"key":"665_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1182\/blood-2006-12-062422","volume":"110","author":"MV Goldberg","year":"2007","unstructured":"Goldberg MV, Maris CH, Hipkiss EL, Flies AS, Zhen L, Tuder RM, et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood. 2007;110:186\u201392.","journal-title":"Blood."},{"key":"665_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450\u201361.","journal-title":"Cancer Cell"},{"key":"665_CR7","unstructured":"OPDIVO\u00ae (nivolumab) US Prescribing Information. Updated November 2018. Available at: https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf . Last Accessed 20 Feb 2019."},{"key":"665_CR8","unstructured":"KEYTRUDA\u00ae (pembrolizumab) US Prescribing Information. Updated December 2018. Available at: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf . Last Accessed 20 Feb 2019)."},{"key":"665_CR9","unstructured":"Libtayo (cemiplimab) Prescribing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761097s000lbl.pdf . Last Accessed 20 Feb 2019."},{"key":"665_CR10","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500\u20131.","journal-title":"N Engl J Med"},{"key":"665_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer genes. Nature. 2013;499:214\u20138.","journal-title":"Nature."},{"key":"665_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, et al. Biomarkers for predicting efficacy of PD-1\/ PD-L1 inhibitors. Mol Cancer. 2018;17:129.","journal-title":"Mol Cancer"},{"key":"665_CR13","doi-asserted-by":"crossref","unstructured":"Bermejo MB, Jaffee EM, Davar D, Cardarelli J, Williams D, Phillips P. Phase 1b\/2 study of nivolumab in combination with an anti\u2013IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer. J Clin Oncol. 2018;36(15_Suppl).","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3109"},{"key":"665_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","volume":"19","author":"JM Wrangle","year":"2018","unstructured":"Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet. 2018;19:694\u2013704.","journal-title":"Lancet."},{"issue":"7_Suppl","key":"665_CR15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.2017.35.7_suppl.97","volume":"35","author":"MR Zibelman","year":"2017","unstructured":"Zibelman MR, Macfarlane A, Alpaugh RK, Dulaimi E, Costello K, O\u2019Neill J, et al. Effect of exogenous interferon-gamma (IFN-gamma) on peripheral blood immune markers as part of a phase I clinical trial of combined IFN-gamma with nivolumab (Nivo) in patients (pts) with select solid tumors. J Clin Oncol. 2017;35(7_Suppl):97.","journal-title":"J Clin Oncol"},{"key":"665_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12094-018-1932-2","volume":"21","author":"V Chung","year":"2019","unstructured":"Chung V, Kos FJ, Hardwick N, et al. Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. Clin Transl Oncol. 2019;21:363\u201372.","journal-title":"Clin Transl Oncol"},{"key":"665_CR17","doi-asserted-by":"crossref","unstructured":"Hamid O, Chow LQM, Tavakkoli F, Marshall S, Gribbin MJ, Karakunnel JJ, et al. Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies. J Clin Oncol. 2015;33(15_suppl) (Abstract TPS3087).","DOI":"10.1200\/jco.2015.33.15_suppl.tps3087"},{"key":"665_CR18","unstructured":"Janku F, Tan DS, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, et al. First-in-human study of FAZ053, an anti-PD-L1 mAb, alone and in combination with spartalizumab, an anti-PD-1 mAb, in patients with advanced malignancies. J Immunother Cancer. 2018;6(suppl 1) Abstract P651."},{"key":"665_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","volume":"27","author":"MJ Butte","year":"2007","unstructured":"Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111\u201322.","journal-title":"Immunity."},{"key":"665_CR20","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/blood-2010-01-265975","volume":"116","author":"JJ Park","year":"2010","unstructured":"Park JJ, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, et al. B7-H1\/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood. 2010;116:1291\u20138.","journal-title":"Blood."},{"key":"665_CR21","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.4049\/jimmunol.1003496","volume":"187","author":"AM Paterson","year":"2011","unstructured":"Paterson AM, Brown KE, Keir ME, Vanguri VK, Riella LV, Chandraker A, et al. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol. 2011;187:1097\u2013105.","journal-title":"J Immunol"},{"key":"665_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/1758834016679942","volume":"9","author":"C Mazza","year":"2017","unstructured":"Mazza C, Escudier B, Albiges L. Nivolumab in renal cell carcinoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2017;9:171\u201381.","journal-title":"Ther Adv Med Oncol"},{"key":"665_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/1756287215597647","volume":"7","author":"M Weinstock","year":"2015","unstructured":"Weinstock M, McDermott D. Targeting PD-1\/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol. 2015;7:365\u201377.","journal-title":"Ther Adv Urol"},{"key":"665_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2146\/ajhp140768","volume":"73","author":"IN Ivashko","year":"2016","unstructured":"Ivashko IN, Kolesar JM. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. Am J Health Syst Pharm. 2016;73:193\u2013201.","journal-title":"Am J Health Syst Pharm"},{"key":"665_CR25","doi-asserted-by":"publisher","first-page":"e967147","DOI":"10.4161\/21624011.2014.967147","volume":"3","author":"L Galluzzi","year":"2014","unstructured":"Galluzzi L, Kroemer G, Eggermont A. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. OncoImmunology. 2014;3:e967147.","journal-title":"OncoImmunology."},{"key":"665_CR26","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2217\/fon.15.52","volume":"11","author":"JR Brahmer","year":"2015","unstructured":"Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol. 2015;11:1307\u201326.","journal-title":"Future Oncol"},{"issue":"15_suppl","key":"665_CR27","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1200\/JCO.2018.36.15_suppl.4500","volume":"36","author":"David F. McDermott","year":"2018","unstructured":"McDermott DF, Lee J-L, Szczylik C, Donskov F, Malik J, Alekseev BY, et al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427. J Clin Oncol. 2018;36(suppl) Abstract 4500.","journal-title":"Journal of Clinical Oncology"},{"key":"665_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3858\/emm.2011.43.10.063","volume":"43","author":"H Shim","year":"2011","unstructured":"Shim H. One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med. 2011;43:539\u201349.","journal-title":"Exp Mol Med"},{"key":"665_CR29","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.jmb.2007.10.034","volume":"374","author":"MS Kim","year":"2007","unstructured":"Kim MS, Lee SH, Song MY, Yoo TH, Lee BK, Kim YS. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol. 2007;374:1374\u201388.","journal-title":"J Mol Biol"},{"key":"665_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","volume":"38","author":"N Emi Aikawa","year":"2010","unstructured":"Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonf\u00e1 E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol. 2010;38:82\u20139.","journal-title":"Clin Rev Allergy Immunol"},{"key":"665_CR31","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020\u201330.","journal-title":"J Clin Oncol"},{"key":"665_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134\u201344.","journal-title":"N Engl J Med"},{"key":"665_CR33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"665_CR34","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","volume":"21","author":"A Patnaik","year":"2015","unstructured":"Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21:4286\u201393.","journal-title":"Clin Cancer Res"},{"key":"665_CR35","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109\u201317.","journal-title":"Lancet."},{"key":"665_CR36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13000-016-0545-8","volume":"11","author":"MC Rebelatto","year":"2016","unstructured":"Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol. 2016;11:95.","journal-title":"Diagn Pathol"},{"key":"665_CR37","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.1074\/jbc.M114.600973","volume":"290","author":"J-P Silva","year":"2015","unstructured":"Silva J-P, Vetterlein O, Jose J, Peters S, Kirby H. The S228P mutation prevents in vivo and in vitro IgG4 fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation. J Biol Chem. 2015;290:5462\u20139.","journal-title":"J Biol Chem"},{"key":"665_CR38","doi-asserted-by":"crossref","unstructured":"Song X, Gao X, Zheng Bo, Black C, Gribbin M, Karakunnel J, et al. Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD1 monoclonal antibody, in patients with advanced malignancies. Cancer Res. 2017;77(13 suppl) (Abstract 5045).","DOI":"10.1158\/1538-7445.AM2017-5045"},{"key":"665_CR39","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60:1421\u201334.","journal-title":"Adv Drug Deliv Rev"},{"key":"665_CR40","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","volume":"21","author":"JS Weber","year":"2016","unstructured":"Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016;21:1230\u201340.","journal-title":"Oncologist."},{"key":"665_CR41","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.2147\/DDDT.S146286","volume":"11","author":"M Wang","year":"2017","unstructured":"Wang M, Ma X, Guo L, Xia F. Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based randomized controlled trials. Drug Des Devel Ther. 2017;11:2851\u201360.","journal-title":"Drug Des Devel Ther"},{"key":"665_CR42","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/17425255.2016.1223047","volume":"12","author":"AC Wong","year":"2016","unstructured":"Wong AC, Ma B. An update on the pharmacodynamics, pharmacokinetics, safety and clinical activity of nivolumab in the treatment of solid cancers. Expert Opin Drug Metab Toxicol. 2016;12:1255\u201361.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"665_CR43","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"665_CR44","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","volume":"22","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin Cancer Res. 2016;22:5461\u201371.","journal-title":"Clin Cancer Res"},{"key":"665_CR45","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","volume":"33","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33:1430\u20137.","journal-title":"J Clin Oncol"},{"key":"665_CR46","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T cell invigoration to tumor burden ratio associated with PD-1 response. Nature. 2017;545:60\u20135.","journal-title":"Nature."},{"key":"665_CR47","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1 targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017;114:4993\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"665_CR48","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nri954","volume":"2","author":"KM Murphy","year":"2002","unstructured":"Murphy KM, Reiner SL. Decision making in the immune system: the lineage decisions of helper T cells. Nat Rev Immunol. 2002;2:933\u201344.","journal-title":"Nat Rev Immunol"},{"key":"665_CR49","doi-asserted-by":"publisher","first-page":"950","DOI":"10.4049\/jimmunol.1401686","volume":"194","author":"R Das","year":"2015","unstructured":"Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, et al. Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo. J Immunol. 2015;194:950\u20139.","journal-title":"J Immunol"},{"key":"665_CR50","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearly JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371.","journal-title":"Nature."},{"key":"665_CR51","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171:934\u201349.","journal-title":"Cell."},{"key":"665_CR52","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-017-0093-8","volume":"5","author":"LP Diggs","year":"2017","unstructured":"Diggs LP, Hsueh EC. Utility of PD-L1 immunohistochemistry assays for predicting PD-1\/PD-L1 inhibitor response. Biomark Res. 2017;5:12.","journal-title":"Biomark Res"},{"key":"665_CR53","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40265-016-0588-x","volume":"76","author":"L Festino","year":"2016","unstructured":"Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, et al. Cancer treatment with anti-PD-1\/PD-L1 agents: is PD-L1 expression a biomarker for patient selection? Drugs. 2016;76:925\u201345.","journal-title":"Drugs."},{"key":"665_CR54","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"J Taube","year":"2014","unstructured":"Taube J, Klein A, Brahmer J, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064\u201374.","journal-title":"Clin Cancer Res"},{"key":"665_CR55","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6:827\u201337.","journal-title":"Cancer Discov"},{"key":"665_CR56","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1172\/JCI87324","volume":"126","author":"A Daud","year":"2016","unstructured":"Daud A, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126:3447\u201352.","journal-title":"J Clin Invest"},{"key":"665_CR57","doi-asserted-by":"publisher","first-page":"e1204507","DOI":"10.1080\/2162402X.2016.1204507","volume":"5","author":"H Inoue","year":"2016","unstructured":"Inoue H, Park JH, Kiyotani K, Zewde M, Miyashita A, Jinnin M, et al. Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology. 2016;5:e1204507.","journal-title":"Oncoimmunology."},{"issue":"15_suppl","key":"665_CR58","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.1200\/jco.2015.33.15_suppl.6017","volume":"33","author":"Tanguy Y. Seiwert","year":"2015","unstructured":"Seiwert TY, Burtness B, Weiss J, Eder JP, Yearley J, Murphy E, et al. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. J Clin Oncol. 2015;33(suppl) Abstract 6017.","journal-title":"Journal of Clinical Oncology"},{"key":"665_CR59","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Luceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340.","journal-title":"J Clin Invest"},{"key":"665_CR60","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","volume":"4","author":"A Ribas","year":"2016","unstructured":"Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, et al. PD-1 blockade expands intratumoral memory T cells. Cancer Immunol Res. 2016;4:194\u2013203.","journal-title":"Cancer Immunol Res"},{"issue":"15_suppl","key":"665_CR61","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1200\/JCO.2016.34.15_suppl.1536","volume":"34","author":"Sarina Anne Piha-Paul","year":"2016","unstructured":"Piha-Paul SA, Bennouna J, Albright A, Nebozhyn M, McClanahan T, Ayers M, et al. T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types. J Clin Oncol. 2016;34(suppl) Abstract 1536.","journal-title":"Journal of Clinical Oncology"},{"key":"665_CR62","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275\u201387.","journal-title":"Nat Rev Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0665-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0665-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0665-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T06:03:29Z","timestamp":1610863409000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0665-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["665"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0665-2","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,22]]},"assertion":[{"value":"11 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with the International Conference on Harmonisation\/Good Clinical Practice and applicable regulatory requirements. The protocol was approved by Institutional Review Boards (IRBs)\/Independent Ethics Committees (IECs) at each center. Patients provided written informed consent to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Aung Naing: Research grants from NCI, EMD Serono, AstraZeneca, Healios Onc., Nutrition, Atterocor, Amplimmune, Karyopharm Therapeutics, Incyte, Regeneron, Merck, BMS, Pfizer, Neon Therapeutics, Calithera BioSciences, and TopAlliance BioSciences; grants and advisory board membership with ARMO BioSciences, Novartis, and CytomX Therapeutics; grants from Immune Deficiency Foundation (spouse).Jeffrey Infante: Consultant for Armo Biosciences and Biomed Valley; employee of Janssen Oncology.Sanjay Goel: Funding to conduct clinical trial from AstraZeneca.Howard Burris: Consultant or advisor to Mersana, AstraZeneca, Bristol-Myers Squibb, FORMA Therapeutics, Janssen, Novartis, Roche\/Genentech, and TG Therapeutics; research funding from Roche\/Genentech, Bristol-Myers Squibb, Incyte, Tarveda Therapeutics, Mersana, AstraZeneca, Macrogenics, Novartis, Boehringer-Ingelheim, Eli Lilly, Seattle Genetics, AbbVie, Bayer, Celldex, Merck, Celgene, Agios, Jounce Therapeutics, Moderna Therapeutics, CytomX Therapeutics, GlaxoSmithKline, Verastem, Tesaro, Immunocore, Takeda, Millennium, BioMed Valley Discoveries, Pfizer, PTC Therapeutics, TG Therapuetics, Loxo, Vertex, eFFECTOR Therapetics, Janssen, Gilead Sciences, Valent Technologies, BioAtla, CicloMed, Harpoon Therapeutics, Jiangsu Hengrui Medicine, Revolution Medicines, Daiichi Sankyo, H3 Biomedicine, Neon Therapeutics, OncoMed, Regeneron, and Sanofi; expert testimony for Novartis.Patricia LoRusso: Advisory boards for Genentech, AstraZeneca, Ipsen, AbbVie, Genmab, Roche, CytomX, and SOTIO; Data Safety Monitoring Boards for Agios, Five Prime, Halozyme, and Tyme.Amy Weise: Speakers\u2019 bureau for Array Biopharma.Joseph Eder: No conflicts to disclose.Brendan Curti: Institution receives research funding from AstraZeneca.Chelsea Black, Shannon Marshall, Ikbel Achour, Rena May, Chris Morehouse, Kristen Pollizzi, Xuyang Song, Keith Steele, Nairouz Elgeioushi, Farzana Walcott, Joyson Karakunnel, and Michael Oberst are current or former employees of AstraZeneca and own stocks\/shares in AstraZeneca. Susannah Barbee is a former employee of Amplimmune.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}